The theory about how reducing beta amyloid plaque could positively effect dementia symptoms has now been shown to be true in a recent report on the drug aducanumab which is an antibody therapy. The medication is likely to be brought to market once approval is obtained and Biogen is going to apply for approval in early 2020.
This drug study result supports what we already know about transcranial photobiomodulation (TPBM) with 1068nm pulsed infrared light stimulation. We also know that there are no adverse side effects with TPBM and the cost of treatment is almost certainly going to be significantly less than lifelong treatment with aducanumab.
Quietmind Foundation has been providing integrative therapy that combines TPBM with home- based, brainwave biofeedback also called neurofeedback) training (NFB) that eliminates the underlying beta amyloid plaque while also increasing mitochondrial health and productivity with NFB to help repair our disrupted brain electrical networks independent of drug or other invasive procedures and unwanted side effects. QMF's longer-term therapy programs are conducted entirely at home by the patient and caregivers, with online training, clinical guidance, and periodic neuropsychiatric and neuropsychophsyiological evaluations at Quietmind Foundation's offices in Philadelphia, New York City, and Los Angeles. Please call Marvin Berman PhD at 610-940-0488 to be considered for one of our ongoing clinical trials or our longer-term comprehensive and individualized neurodegeneration treatment program.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.